Key Points
- Insider sale: Gregory Weinhoff sold 73,196 shares at $26.33 for $1,927,250.68, cutting his stake by 52.61% to 65,925 shares (valued ≈ $1.74M).
- Stock context: CNTA opened at $26.33 and was down about 3.3%, with a market cap of $3.85B and a 52‑week range of $9.60 to $30.58.
- Analyst outlook: The consensus rating is “Buy” with a $39.80 average price target, and several firms (including Oppenheimer and Truist) recently raised their targets.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) insider Gregory Weinhoff sold 73,196 shares of the company's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the sale, the insider owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Centessa Pharmaceuticals Stock Down 3.3%
Shares of NASDAQ CNTA opened at $26.33 on Friday. The stock has a market capitalization of $3.85 billion, a P/E ratio of -14.39 and a beta of 1.55. The stock's fifty day moving average is $24.69 and its 200 day moving average is $24.24. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $80,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Coastal Bridge Advisors LLC increased its position in Centessa Pharmaceuticals by 7.1% during the 4th quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company's stock worth $351,000 after purchasing an additional 931 shares in the last quarter. XTX Topco Ltd acquired a new position in Centessa Pharmaceuticals during the 4th quarter worth approximately $1,978,000. Finally, Voloridge Investment Management LLC bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $8,710,000. Institutional investors and hedge funds own 82.01% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on CNTA shares. Truist Financial raised their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Chardan Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. TD Cowen reissued a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Oppenheimer boosted their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday, December 10th. Finally, B. Riley Financial upped their target price on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $39.80.
Get Our Latest Stock Report on Centessa Pharmaceuticals
About Centessa Pharmaceuticals
(
Get Free Report)
Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.
Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
